Patents Examined by Jia-Hai Lee
  • Patent number: 11135230
    Abstract: The invention provides lipid compositions comprising phospholipids having a high docosahexaenoic acid (DHA) content, which compositions are preferably extracted from natural sources. The lipid compositions are excellent sources of highly bioavailable DHA and they can be used in oral delivery vehicles, dietary supplements, functional foods, and the like.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: October 5, 2021
    Assignee: Arctic Nutrition AS
    Inventors: Hogne Hallaraker, Jan Remmereit, Alvin Berger
  • Patent number: 11066442
    Abstract: Disclosed herein are deuterated compounds, pharmaceutical compositions thereof, and methods for treating ETBR-related cancers. Also disclosed herein is a delivery system for the controlled, systemic release of at least one deuterated ETBR antagonist, optionally in conjunction with an additional anti-oncologic agent.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: July 20, 2021
    Assignee: ENB Therapeutics, Inc.
    Inventor: Sumayah Jamal
  • Patent number: 11059870
    Abstract: Disclosed is a polypeptide having a phase transition behavior, wherein the polypeptide consists of a Val-Pro-Gly-Xaa-Gly (SEQ ID NO: 1) pentapeptide repeat or a Val-Pro-Ala-Xaa-Gly (SEQ ID NO: 2) pentapeptide repeat, and the polypeptide includes a [Val-Pro-Gly-Xaa-Gly (SEQ ID NO: 1)]n or a [Val-Pro-Ala-Xaa-Gly (SEQ ID NO: 1)]n pentapeptide repeat. In addition, the present invention provides a multi-stimuli polypeptide composed of polypeptide-calmodulin-polypeptide having a phase transition behavior and a hydrogel prepared using the same. A dynamic protein hydrogel according to the present invention may be used as a drug carrier, as a scaffold for tissue engineering or as a kit for tissue or organ regeneration.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: July 13, 2021
    Assignee: Industry-University Cooperation Foundation Hanyang University Erica Campus
    Inventors: Dong Woo Lim, Jae Sang Lee, Min Jung Kang
  • Patent number: 11053301
    Abstract: Described herein are methods and compositions relating to nanodiscs, e.g., phospholipid bilayers with a proteinaceous belt or border. Further provided herein are loopable membrane scaffold proteins, e.g., for forming nanodiscs.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: July 6, 2021
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gerhard Wagner, Mahmoud Nasr
  • Patent number: 10874745
    Abstract: Antimicrobial agents, including antimicrobial peptides (AMPs), and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptide variants that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPs change selectivity from broad spectrum antimicrobial activity to Gram-negative selectivity.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: December 29, 2020
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Robert S. Hodges, Ziqing Jiang, Lajos Gera, Colin T. Mant
  • Patent number: 10842728
    Abstract: The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from Brachiostoma lanceolatum.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: November 24, 2020
    Assignee: Allele Biotechnology & Pharmaceuticals, Inc.
    Inventor: Jiwu Wang
  • Patent number: 10808010
    Abstract: Disclosed herein are isolated peptides inhibit activity of a cofactor-independent phosphoglycerate mutase. In some examples, the isolated peptide is 6-20 amino acids long and includes the amino acid sequence of any one of SEQ ID NOs: 1-22 or 54, an analog or derivative thereof, or a pharmaceutically acceptable salt or ester thereof. In some examples, the peptide is a cyclic peptide with an N-terminal ring of 6-15 amino acids (for example, 6-10 amino acids) and a C-terminal linear portion of 1-9 amino acids (for example, 3-8 amino acids. Also disclosed h are methods of treating or inhibiting an infection in a subject, including administering to the subject an effective amount of a composition including one of more of the disclosed peptides, or analogs or derivative thereof, or pharmaceutically acceptable salts or esters thereof.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: October 20, 2020
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The University of Tokyo, New England Biolabs, Inc.
    Inventors: James Inglese, Patricia Dranchak, Ryan MacArthur, Hiroaki Suga, Hao Yu, Clotilde Carlow, Zhiru Li
  • Patent number: 10709768
    Abstract: Disclosed is a novel peptide capable of preventing or treating ocular surface disease by inhibiting or improving pathological changes caused by neovascularization, opacification, fibrosis and inflammation of the cornea, the peptide having an amino acid sequence represented by SEQ ID NO: 1 and more particularly, provides a collagen type II ?1-based peptide isolated from an animal chondrocyte cell-derived extracellular matrix and use thereof.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: July 14, 2020
    Assignee: EYEBIO KOREA
    Inventor: Jae Wook Yang
  • Patent number: 10653749
    Abstract: The invention provides cell-permeable Ga-Interacting Vesicle associated protein (GIV)-derived peptides and their use for treatment of diverse diseases. The invention further provides C-terminus of Ga-Interacting Vesicle associated protein (GIV-CT)-based peptides and GIV-CT encoding vectors and methods of use thereof, for successfully manipulating the diverse pathophysiologic processes in which GIV has been implicated. In one aspect, the invention provides cell-permeable peptides PTD-GIV-CT comprising (i) a peptide transduction domain (PTD) and (ii) a C-terminus of Ga-Interacting Vesicle associated protein (GIV-CT) or a mutant thereof. In one embodiment, said peptides are capable of activating Gi downstream of receptor tyrosine kinases (RTKs). The invention also provides pharmaceutical compositions comprising one or more of the peptides of the invention as well as vectors encoding such peptides.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: May 19, 2020
    Assignee: The Regents of the University of California
    Inventor: Pradipta Ghosh
  • Patent number: 10646593
    Abstract: The present disclosure provides activatable and detectable membrane-interacting peptides that, following activation, can interact with phospholipid bilayers, such as cell membranes. The present disclosure also provides methods of use of such compounds. The compounds of the present disclosure are of the general structure X1a-A-X2-Z-X1b, where A is a membrane-interacting peptide region having a plurality of nonpolar hydrophobic amino acid residues that, following separation from portions Z, is capable of interaction with a phospholipid bilayer; Z is an inhibitory peptide region that can inhibit the activity of portion A; X2 is a cleavable linker that can be cleaved to release cleavage products from the compound; and X1a and X1b are optionally-present chemical handles that facilitate conjugation of various cargo moieties to the compound. Prior to cleavage of the composition at X2, the composition acts as a promolecule that does not associate with cellular membranes to a significant or detectable level.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: May 12, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michael Page, Charles S. Craik
  • Patent number: 10624968
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: April 21, 2020
    Assignee: BICYCLERD LIMITED
    Inventors: Gavin Bennett, Daniel Paul Teufel
  • Patent number: 10617975
    Abstract: The present invention refers to a method for the separation of peptide aggregates and fragments from solutions containing target peptide.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: April 14, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Romas Skudas, Klaus Adrian, Bianca Edelmann, Matthias Joehnck
  • Patent number: 10584146
    Abstract: Heme released as a result of sustained injury leads to toxicity and triggers an inflammatory response and tissue damage. Heme oxygenase, an enzyme, recognizes, binds free heme and breaks it down as a part of the anti-inflammatory response. The present disclosure relates to a class of peptide amphiphiles that mimic the heme oxygenase function, and have shown that the designed peptide is able to bind and break down heme thus validating its potential as an anti-inflammatory agent that promotes tissue repair and useful in wound healing. The disclosed peptide sequence design provides control of amphiphile peptides' supramolecular structure and function. Applicants have shown that the incorporated heme molecule can transport CO, which suggests that the peptides can also transport NO, O2 and reactive oxygens, the molecules which are responsible for vasodilation, neurotransmission and cell death.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: March 10, 2020
    Assignee: UChicago Argonne, LLC
    Inventors: Harry C. Fry, Lee A. Solomon
  • Patent number: 10583174
    Abstract: The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: March 10, 2020
    Assignee: SANOFI
    Inventors: Britta Göbel, Mark Sommerfeld, Oliver Boscheinen, Thomas Langer, Christine Rudolph, Andreas Evers
  • Patent number: 10577391
    Abstract: Disclosed herein are formulations, substrates, and arrays for amino acid and peptide synthesis on microarrays. In certain embodiments, methods for manufacturing and using the formulations, substrates, and arrays including one-step coupling, e.g., for synthesis of peptides in a C?N orientation are disclosed. In some embodiments, disclosed herein are formulations and methods for high efficiency coupling of biomolecules to a substrate.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: March 3, 2020
    Assignee: Vibrant Holdings, LLC
    Inventor: Vasanth Jayaraman
  • Patent number: 10538558
    Abstract: The present invention provides compositions comprising peptides derived from amino acid sequences (or from combinations thereof) of fusion and other protein regions of various viruses, including but not limited to, severe acute respiratory syndrome coronavirus, herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend murine leukemia virus; human T lymphotropic virus type 1; herpesvirus ateles; Marburg virus; Sudan Ebola virus; Zaire Ebola virus, and comprising L- and/or D-amino acids and combinations thereof, which affect T cells by acting on the T cell antigen receptor (TCR). More specifically, the peptides act on the TCR??-CD3??-CD3??-?? signaling complex. Yet more specifically, the peptides act on the TCR?/CD3??/?? signaling module of TCR. The present invention further relates to the prevention and therapy of various T cell-related disease states involving the use of these compositions.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: January 21, 2020
    Assignee: SIGNABLOK, INC
    Inventor: Alexander B. Sigalov
  • Patent number: 10532084
    Abstract: Disclosed is a novel peptide capable of preventing or treating ocular surface disease by inhibiting or improving pathological changes caused by neovascularization, opacification, fibrosis and inflammation of the cornea, the peptide having an amino acid sequence represented by SEQ ID NO: 1 and more particularly, provides a collagen type II ?1-based peptide isolated from an animal chondrocyte cell-derived extracellular matrix and use thereof.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: January 14, 2020
    Assignee: EYEBIO KOREA
    Inventor: Jae Wook Yang
  • Patent number: 10532085
    Abstract: The present invention relates to a bioactive agent capable of increasing the intracellular concentration and/or activity of Hsp70 for use in the treatment of a lysosomal storage disease which arise from a defect in an enzyme whose activity is not directly associated with the presence of lysosomal BMP as a co-factor; such as glycogen storage diseases, gangliosidoses, neuronal ceroid lipofuscinoses, cerebrotendinous cholesterosis, Wolman's disease, cholesteryl ester storage disease, disorders of glycosaminoglycan metabolism, mucopolysaccharidoses, disorders of glycoprotein metabolism, mucolipidoses, aspartylglucosaminuria, fucosidosis, mannosidoses, and sialidosis type II.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: January 14, 2020
    Assignee: Orphazyme A/S
    Inventors: Thomas K. Jensen, Anders Mørkeberg Hinsby
  • Patent number: 10526369
    Abstract: The present invention provides a cell penetrating peptide dimer by oxidative modification, in which each monomer is connected with each other by the disulfide linkage. The drugability of the peptide dimer has been improved through enhancing stability, reducing proteolysis, retaining permeability and increasing heparan sulfate binding specificity. The modified peptide products can be used to deliver drug molecules as a suitable drug carrier for targeted therapy.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: January 7, 2020
    Inventors: Yu-Min Lin, Wei-Chen Chen, Win-Chin Chiang, Ting Lian Chang, Chun-Hung Kuo
  • Patent number: 10525107
    Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: January 7, 2020
    Assignee: Alkahest, Inc.
    Inventors: David Bell, Ian Gallager, Steven P. Braithwaite, S. Sakura Minami, Vu Dang, Joe McCracken, Karoly Nikolich